Novo Nordisk hemophilia drug moves closer to approval in Japan
COPENHAGEN (Reuters) - NovoEight, a hemophilia drug made by Denmark's Novo Nordisk, is a step closer to marketing approval in Japan after it passed a review by the country's drugs committee.
Novo, the world's biggest insulin producer, said in a statement on Monday that it expects to receive marketing authorization within a few months.
The remaining step in the regulatory process is an official approval from the Ministry of Health, Labor and Welfare, to which the Committee on Drugs serves as an advisory body.
(Reporting by Mette Fraende; Editing by David Goodman)
- British Muslims blame jihadi subculture after beheading video |
- Israeli air strike kills three Hamas commanders in Gaza |
- U.S. aid workers who survived Ebola leave Atlanta hospital |
- Obama condemns killing of reporter, U.S. hits militants in Iraq |
- Ukraine border guards begin checks on Russian aid trucks
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video